- Home
- INBX vs CGEN Comparison
INBX vs CGEN Comparison
Compare INBX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- CGEN
- Stock Information
- Founded
- INBX 2010
- CGEN 1993
- Country
- INBX United States
- CGEN Israel
- Employees
- INBX N/A
- CGEN N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INBX Health Care
- CGEN Health Care
- Exchange
- INBX Nasdaq
- CGEN Nasdaq
- Market Cap
- INBX 178.5M
- CGEN 167.4M
- IPO Year
- INBX 2020
- CGEN 2000
- Fundamental
- Price
- INBX $21.73
- CGEN $1.59
- Analyst Decision
- INBX Hold
- CGEN
- Analyst Count
- INBX 1
- CGEN 0
- Target Price
- INBX N/A
- CGEN N/A
- AVG Volume (30 Days)
- INBX 122.5K
- CGEN 162.2K
- Earning Date
- INBX 08-12-2025
- CGEN 08-05-2025
- Dividend Yield
- INBX N/A
- CGEN N/A
- EPS Growth
- INBX N/A
- CGEN N/A
- EPS
- INBX 111.58
- CGEN N/A
- Revenue
- INBX $200,000.00
- CGEN $27,589,000.00
- Revenue This Year
- INBX N/A
- CGEN N/A
- Revenue Next Year
- INBX N/A
- CGEN $173.80
- P/E Ratio
- INBX $0.20
- CGEN N/A
- Revenue Growth
- INBX N/A
- CGEN N/A
- 52 Week Low
- INBX $10.80
- CGEN $1.13
- 52 Week High
- INBX $22.31
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- INBX 84.22
- CGEN 44.35
- Support Level
- INBX $13.97
- CGEN $1.66
- Resistance Level
- INBX $15.25
- CGEN $1.74
- Average True Range (ATR)
- INBX 1.10
- CGEN 0.10
- MACD
- INBX 0.66
- CGEN -0.02
- Stochastic Oscillator
- INBX 95.32
- CGEN 8.00
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.